Analysts forecast that The Medicines Company (NASDAQ:MDCO) will announce earnings per share (EPS) of ($1.48) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for The Medicines’ earnings, with estimates ranging from ($1.72) to ($1.11). The Medicines reported earnings of ($1.77) per share in the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The business is expected to issue its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that The Medicines will report full year earnings of ($8.86) per share for the current fiscal year, with EPS estimates ranging from ($9.10) to ($8.48). For the next financial year, analysts anticipate that the firm will post earnings of ($3.95) per share, with EPS estimates ranging from ($4.02) to ($3.87). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow The Medicines.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $26.06 million. During the same quarter in the prior year, the firm earned ($0.64) EPS. The company’s revenue for the quarter was down 55.1% on a year-over-year basis.

MDCO has been the subject of several research analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $85.00 price objective (up previously from $80.00) on shares of The Medicines in a research note on Tuesday, August 29th. Zacks Investment Research cut shares of The Medicines from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 10th. Guggenheim initiated coverage on shares of The Medicines in a research note on Monday, October 23rd. They set a “buy” rating and a $45.00 price objective for the company. Jefferies Group reaffirmed a “buy” rating and set a $54.00 price objective on shares of The Medicines in a research note on Thursday, September 14th. Finally, Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the company a “hold” rating in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $53.67.

The Medicines (NASDAQ:MDCO) traded down $0.50 on Friday, hitting $28.50. 1,412,108 shares of the company traded hands, compared to its average volume of 1,063,842. The Medicines has a 52-week low of $27.77 and a 52-week high of $55.95. The company has a debt-to-equity ratio of 3.42, a current ratio of 2.31 and a quick ratio of 1.79.

In related news, Director Alexander J. Denner acquired 170,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the transaction, the director now owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.22% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. First Mercantile Trust Co. lifted its holdings in The Medicines by 2.5% during the 2nd quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after buying an additional 114 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in The Medicines by 0.6% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 39,599 shares of the company’s stock worth $1,505,000 after buying an additional 219 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in The Medicines by 4.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock worth $230,000 after buying an additional 243 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in The Medicines by 10.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after buying an additional 264 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in The Medicines by 1.1% during the 2nd quarter. Arizona State Retirement System now owns 37,596 shares of the company’s stock worth $1,429,000 after buying an additional 400 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “The Medicines Company (MDCO) Expected to Post Earnings of -$1.48 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/03/the-medicines-company-mdco-expected-to-post-earnings-of-1-48-per-share.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.